Second-trimester maternal serum markers (triple test) is common used to estimate 
of the fetal risk of genetic abnormalities and open neural tube defects. 
Positive results of the triple test concomitant with the normal fetus karyotype 
pattern can also predict the adverse pregnancy outcome. Many authors have been 
indicated such false positive results of the triple test in the cases of the 
uterine myomas, PIH, IUGR, and IUD.
OBJECTIVE: The purpose of this study was to determine the association between 
abnormal second trimester Down syndrome screening markers and adverse pregnancy 
outcome.
MATERIAL AND METHODS: A total of 775 pregnant women underwent maternal serum 
screening. Pregnancy complications were studied in the groups of pregnancies 
with structurally and chromosomally normal fetuses--with: elevated AFP > 
1,89MoM, elevated beta-hCG > 1,69MoM or low beta-hCG < 0,48MoM.
RESULTS: Increased maternal serum AFP > 1,89MoM were found to be significantly 
associated with IUGR, PIH and placental pathology. Increased beta-hCG > 1,69MoM 
were significantly associated with PIH and IUGR. Finally decreased beta-hCG < 
0,48MoM were found to be significantly associated with IUGR, PIH and IUD.
CONCLUSION: Triple test can be used not only for the detection of fetal 
chromosomal and NTD abnormalities but also for the detection of high-risk 
pregnancies.